Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jodi Braley"'
Autor:
Naranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, Jinghua Feng, Daniel Thomson, Paul Wang, Verity Saunders, Chung Hoow Kok, Rob M. King, Rosalie R. Kenyon, Ming Lin, Ilaria S. Pagani, David M. Ross, Agnes S.M. Yong, Andrew P. Grigg, Anthony K. Mills, Anthony P. Schwarer, Jodi Braley, Haley Altamura, David T. Yeung, Hamish S. Scott, Andreas W. Schreiber, Timothy P. Hughes, Susan Branford
Publikováno v:
Haematologica, Vol 108, Iss 9 (2023)
The BCR::ABL1 gene fusion initiates chronic myeloid leukemia (CML); however, evidence has accumulated from studies of highly selected cohorts that variants in other cancer-related genes are associated with treatment failure. Nevertheless, the true in
Externí odkaz:
https://doaj.org/article/7ba038cd17a1438e95c1c0d3b1a833dc
Autor:
Ilaria S. Pagani, Phuong Dang, Ivar O. Kommers, Jarrad M. Goyne, Mario Nicola, Verity A. Saunders, Jodi Braley, Deborah L. White, David T. Yeung, Susan Branford, Timothy P. Hughes, David M. Ross
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
Accurate quantification of minimal residual disease (MRD) during treatment of chronic myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR for BCR-ABL1 mRNA, reflects a composite of the number of circulating leukemic
Externí odkaz:
https://doaj.org/article/6e9ce5e0c1a942b48101aceeb7ec37ba
Autor:
Agnes S. M. Yong, Sophie Watts, Randall H. Grose, Timothy P. Hughes, Phuong Dang, Susan Branford, David T Yeung, Ilaria S. Pagani, Chung H. Kok, Zandy Rwodzi, Haley Altamura, Naranie Shanmuganathan, Jennifer McLean, Verity A Saunders, Lisa Carne, Jodi Braley, David M. Ross, Deborah L. White
Publikováno v:
Leukemia. 34:1052-1061
Approximately half of patients with chronic myeloid leukemia (CML) in sustained deep molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment-free remission (TFR). Some of these patients have measurable residual diseas
Autor:
Jodi Braley, David T Yeung, Ilaria S. Pagani, David M. Ross, Susan Branford, Naranie Shanmuganathan, Timothy P. Hughes, Haley Altamura, Agnes S.M. Yong, Sa-Hee Park, Dong-Wook Kim, Devendra K Hiwase
With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR by improving our understanding of its key determinants. Chronic-phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c69cb41c5f382d22dda8d186602db83
https://hdl.handle.net/11541.2/146278
https://hdl.handle.net/11541.2/146278
Autor:
David M. Ross, Jodi Braley, Timothy P. Hughes, Phuong Dang, Ilaria S. Pagani, Ivar O. Kommers, Verity A Saunders, Deborah L. White, Jarrad M. Goyne, Susan Branford, Mario Nicola, David T Yeung
Publikováno v:
Haematologica, 103(12), 2026-2032. Ferrata Storti Foundation
Pagani, I S, Dang, P, Kommers, I O, Goyne, J M, Nicola, M, Saunders, V A, Braley, J, White, D L, Yeung, D T, Branford, S, Hughes, T P & Ross, D M 2018, ' BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia ', Haematologica, vol. 103, no. 12, pp. 2026-2032 . https://doi.org/10.3324/haematol.2018.189787
Pagani, I S, Dang, P, Kommers, I O, Goyne, J M, Nicola, M, Saunders, V A, Braley, J, White, D L, Yeung, D T, Branford, S, Hughes, T P & Ross, D M 2018, ' BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia ', Haematologica, vol. 103, no. 12, pp. 2026-2032 . https://doi.org/10.3324/haematol.2018.189787
Accurate quantification of minimal residual disease during treatment of chronic myeloid leukaemia guides clinical decisions. The conventional minimal residual disease method, RQ-PCR for BCR-ABL1 mRNA, reflects a composite of the number of circulating
Autor:
Timothy P. Hughes, Naranie Shanmuganathan, Agnes S. M. Yong, Jodi Braley, David M. Ross, Devendra K Hiwase, Susan Branford, David T Yeung
With the increasing adoption of treatment-free remission (TFR) as a goal for patients with chronic myeloid leukemia (CML), rigorous molecular monitoring has been recommended to ensure timely tyrosine kinase inhibitor (TKI) recommencement in the event
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3557c924fa60289d0694e0cf19e7325
https://hdl.handle.net/11541.2/138641
https://hdl.handle.net/11541.2/138641
Autor:
Martin C. Mueller, David M. Ross, David T Yeung, Andreas W. Schreiber, Timothy P. Hughes, Daniel Thomson, Jodi Braley, Nur Hezrin Shahrin, Wendy T Parker, Agnes S. M. Yong, Deborah L. White, Christian Dietz, Naranie Shanmuganathan, Jasmina Georgievski, Soo-Hyun Kim, Carol Wadham, Susan Branford, Dong-Wook Kim, Anna L. Brown, Joel Geoghegan, Adrian Purins, Justine E Marum, Jinghua Feng, Soo Young Choi, Christopher N. Hahn, Nathalie Nataren, Doris Stangl, Paul Wang, Hamish S. Scott, Haley Altamura, Sa-Hee Park, Ieuan Walker, Zoe R. Donaldson
Publikováno v:
Blood. 132(9)
Genomic events associated with poor outcome in chronic myeloid leukemia (CML) are poorly understood. We performed whole-exome sequencing, copy-number variation, and/or RNA sequencing for 65 patients to discover mutations at diagnosis and blast crisis
Autor:
John F. Seymour, David T Yeung, Ilaria S. Pagani, Susan Branford, David M. Ross, Christopher Arthur, Deborah L. White, Anthony K. Mills, Naranie Shanmuganathan, Robin Filshie, Andrew Grigg, Agnes S. M. Yong, Timothy P. Hughes, Chung H. Kok, Verity A Saunders, Jodi Braley, Anthony P. Schwarer, Phuong Dang
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs), approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and remain in treatment-free remission (TFR). The ALLGCML8 study enrolle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d07859e77ae88ea2e1c85ee866a1ca24
https://hdl.handle.net/11541.2/134816
https://hdl.handle.net/11541.2/134816
Autor:
A. Yong, D.T. Yeung, S.M. Watts, D.M. Ross, P. Dang, Jodi Braley, L. Carne, Verity A Saunders, Z. Rwodzi, R. Grose, T.P. Hughes, J. McLean, D.L. White, S. Branford, N. Shanmuganathan, I.S. Pagani
Publikováno v:
HemaSphere. 3:398
Autor:
Andrew Grigg, Yiu Lam Kwan, David T Yeung, Mark P. Hertzberg, Michael Kornhauser, Anthony K. Mills, Michael Osborn, Samar Issa, Constantine S. Tam, Robin Filshie, Judith Trotman, Deborah L. White, Timothy P. Hughes, Devendra K Hiwase, Susan Branford, Jennifer Beresford, John Taper, Christopher Arthur, David M. Ross, Cecily Forsyth, Alan Herschtal, Jodi Braley, Anthony P. Schwarer
The therapeutic intensification in De Novo Leukaemia (TIDEL)-II study enrolled 210 patients with chronic phase chronic myeloid leukemia (CML) in two equal, sequential cohorts. All started treatment with imatinib 600 mg/day. Imatinib plasma trough lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e726b12e39a16f4928143bb20a8f8186
https://hdl.handle.net/11541.2/117450
https://hdl.handle.net/11541.2/117450